Jefferies Group Comments on Thermo Fisher Scientific Inc.'s FY2017 Earnings (TMO)

Postado Mai 19, 2017

Independent Portfolio Consultants Inc. raised its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Shelton Capital Management stated it has 0.15% of its portfolio in Thermo Fisher Scientific Inc. The fund owned 25,712 shares of the medical research company's stock after buying an additional 122 shares during the period. Tiverton Asset Management LLC raised its stake in shares of Thermo Fisher Scientific by 147.6% in the third quarter.

Northeast Investment Management decreased Wayfair Inc (NYSE:W) stake by 114,633 shares to 31,273 valued at $1.10M in 2016Q4. Dorsey & Whitney Trust CO LLC now owns 3,079 shares of the medical research company's stock valued at $490,000 after buying an additional 21 shares during the last quarter. Washington Trust Bank raised its stake in shares of Thermo Fisher Scientific by 0.5% in the first quarter.

A number of hedge funds have recently modified their holdings of the stock. (NYSE:TMO) by 30.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,455 shares of the medical research company's stock after buying an additional 1,447 shares during the period. $3.17 million worth of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.01% during trading on Tuesday, reaching $172.27. Following the completion of the transaction, the insider now directly owns 41,277 shares of the company's stock, valued at approximately $6,965,906.52. Jefferies Group also issued estimates for Thermo Fisher Scientific's Q1 2018 earnings at $2.43 EPS, Q2 2018 earnings at $2.52 EPS, Q3 2018 earnings at $2.47 EPS, Q4 2018 earnings at $2.69 EPS and FY2018 earnings at $10.10 EPS. The company's 50-day moving average is $161.19 and its 200-day moving average is $152.40.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 26th.

Analysts expect Bollente Companies Inc (OTCMKTS:BOLC) to report $0.00 EPS on June, 5. The firm had revenue of $4.77 billion for the quarter, compared to analysts' expectations of $4.68 billion. Thermo Fisher Scientific had a return on equity of 15.41% and a net margin of 11.06%. Thermo Fisher Scientific's revenue was up 10.9% on a year-over-year basis. During the same quarter previous year, the firm posted $1.80 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post $9.21 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 17th. The ex-dividend date of this dividend was Monday, March 13th. (NYSE:TMO) to report earnings on July, 27. Deutsche Bank AG boosted their price objective on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a "buy" rating in a research note on Friday, April 28th. Finally, Jefferies Group LLC restated a "hold" rating and set a $160.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, March 29th. Barclays PLC restated an "overweight" rating and set a $190.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, May 9th. Finally, Evercore ISI boosted their target price on shares of Thermo Fisher Scientific from $160.00 to $162.00 and gave the stock a "buy" rating in a research report on Tuesday, January 31st.

Among 14 analysts covering Thermo Fisher Scientific (NYSE:TMO), 12 have Buy rating, 0 Sell and 2 Hold. Leerink Swann reinitiated Thermo Fisher Scientific Inc. Also, CEO Marc N. Casper sold 20,000 shares of the business's stock in a transaction dated Wednesday, March 15th. $183.75 target price is just $8.25 shy of the official lowest sell-side analyst price target on Wall Street. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The shares were sold at an average price of $158.71, for a total value of $642,616.79. Following the transaction, the senior vice president now owns 42,809 shares in the company, valued at $6,794,216.39. The disclosure for this sale can be found here. Insiders have sold a total of 57,964 shares of company stock worth $9,215,579 over the last 90 days. United Capital Financial Advisers Limited Co accumulated 112,220 shares or 0.15% of the stock.

The biotech company Thermo Fisher Scientific has agreed to buy the drug-ingredients maker Patheon in a $7.2 billion deal. The Firm provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.